RESEARCH TRIANGLE PARK, N.C. – March 17, 2006 – Quintiles Transnational Corp. ("Quintiles") and Pharma Services Intermediate Holding Corp. ("Holding;" each of Holding and Quintiles, is referred to as a "Company") today announced that, in connection with the previously announced tender offer and consent solicitation for any and all of Quintiles' outstanding $450.0 million aggregate principal amount 10% senior subordinated notes due 2013 (CUSIP Nos. 748767 AE0 and 748767 AD2)(the "Subordinated Notes") and any and all of Holding's outstanding $219.0 million aggregate principal amount at maturity 11.5% senior discount notes due 2014 (CUSIP No. 71711W AB6)(the "Discount Notes"), the requisite consents have been received to approve certain amendments to the indentures under which the respective Notes were issued. The amendments to the indentures will eliminate or make less restrictive most of the restrictive covenants contained in the indentures and amend certain related provisions.
Approximately $446.0 million principal amount, or 99.1%, of the outstanding principal amount of the Subordinated Notes and $219.0 million principal amount at maturity, or 100.0%, of the outstanding principal amount at maturity of the Discount Notes, and the consents related thereto, have been validly tendered by the consent payment deadline of 5:00 p.m. New York City time, Thursday, March 16, 2006 (the "Consent Payment Deadline"). Each Company expects to execute a supplemental indenture incorporating the amendments with Wells Fargo Bank, N.A., as trustee under each indenture, as described in the Companies' Offer to Purchase and Consent Solicitation Statement, dated March 3, 2006, as soon as practical. However, the amendments will not become operative unless and until the Companies purchase the validly tendered Notes pursuant to the tender offer.
All withdrawal rights of tendering holders of Notes terminated at 5:00, p.m., New York City time on Thursday, March 16, 2006. Accordingly, tendering holders may no longer withdraw their Notes. Holders who have not yet tendered their Notes may tender at or prior to 12:00 midnight on Thursday, March 30, 2006. Quintiles and Holding have elected to pay the total consideration, including the consent payment, for all validly tendered Notes, including those tendered subsequent to the Consent Payment Deadline. The total consideration and the consent payment for the Notes are each described in the Offer to Purchase. Each Company's obligation to consummate the tender offer is subject to the prior satisfaction or waiver of the conditions precedent described in the Offer to Purchase.
The Companies have engaged Citigroup Corporate and Investment Banking to act as dealer manager in connection with the tender offer. Questions regarding the tender offer may be directed to Citigroup at (800) 558-3745 (toll-free) and (212) 723-6106 (collect). Requests for documentation may be directed to Global Bondholder Services Corporation, the tender agent and information agent for the tender offer, at (866) 873-7700 (toll free) or (212) 430-3774.
This press release does not constitute an offer to buy, the solicitation of an offer to sell or the solicitation of consents with respect to the Notes. In accordance with any state securities laws applicable to the tender offer in the United States which require the tender offer to be made to the public by a licensed broker or dealer, the tender offer shall be deemed to be made to the holders of Notes residing in those states by Citigroup on behalf of the Companies. The tender offer and solicitation of consents is made solely pursuant to the Offer to Purchase and Consent Solicitation Statement dated March 3, 2006.
Quintiles is the global leader in pharmaceutical services. We improve healthcare worldwide by providing innovative, quality professional expertise, market intelligence and partnering solutions to meet the dynamic needs of the pharmaceutical, biotechnology and healthcare industries. Quintiles has 16,000 specialized employees and offices in 50 countries. For more information visit the company's Web site at www.quintiles.com.
Information in this press release contains "forward-looking statements." These statements involve risks and uncertainties that could cause actual results to differ materially, including, without limitation, the possibility that Quintiles may not be able to secure financing on terms acceptable to Quintiles prior to the expiration of the tender offer or otherwise obtain funds sufficient to purchase the Notes tendered and pay the related consent payments and fees and expenses in connection therewith. Additional factors that could cause actual results to differ materially are discussed in Quintiles' recent filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, its Form 8-Ks and its other periodic reports, including Form 10-Qs. Any forward-looking statements are as of the date hereof, and we have no duty to update them if our views later change.